Ziad Bakouny outlines his research into the determinants of the poor prognosis and response to immune checkpoint inhibitors seen in patients with sarcomatoid and rhabdoid renal cell carcinoma (4:14).
15-02-2020 | ASCO GU 2020 | Conference coverage | Video